Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415051 · ClinicalTrials.gov registry record · Phase 2
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00415051 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 20 participants.
The verdict
NCT00415051, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.
Interventions
- BIOLOGICAL RVF MP-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415051
The ClinicalTrials.gov registry entry for NCT00415051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RVF MP-12 is the first listed.
NCT00415051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415051 about?
NCT00415051 is a clinical study titled "Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine". This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into...
What is the current status of trial NCT00415051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00415051?
The interventions under investigation include: RVF MP-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00415051?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.